PT3934637T - (n-)acetil-l-leucina para utilização no tratamento de lesão cerebral traumática - Google Patents

(n-)acetil-l-leucina para utilização no tratamento de lesão cerebral traumática

Info

Publication number
PT3934637T
PT3934637T PT207120296T PT20712029T PT3934637T PT 3934637 T PT3934637 T PT 3934637T PT 207120296 T PT207120296 T PT 207120296T PT 20712029 T PT20712029 T PT 20712029T PT 3934637 T PT3934637 T PT 3934637T
Authority
PT
Portugal
Prior art keywords
leucine
acetyl
treating disease
related analogs
analogs
Prior art date
Application number
PT207120296T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of PT3934637T publication Critical patent/PT3934637T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT207120296T 2019-03-02 2020-03-02 (n-)acetil-l-leucina para utilização no tratamento de lesão cerebral traumática PT3934637T (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962812987P 2019-03-02 2019-03-02
US201962842296P 2019-05-02 2019-05-02
US201962888894P 2019-08-19 2019-08-19
US201962895144P 2019-09-03 2019-09-03

Publications (1)

Publication Number Publication Date
PT3934637T true PT3934637T (pt) 2024-08-30

Family

ID=69845470

Family Applications (1)

Application Number Title Priority Date Filing Date
PT207120296T PT3934637T (pt) 2019-03-02 2020-03-02 (n-)acetil-l-leucina para utilização no tratamento de lesão cerebral traumática

Country Status (25)

Country Link
US (1) US20220142959A1 (cg-RX-API-DMAC10.html)
EP (2) EP4464378A3 (cg-RX-API-DMAC10.html)
JP (2) JP7555346B2 (cg-RX-API-DMAC10.html)
KR (2) KR102941068B1 (cg-RX-API-DMAC10.html)
CN (2) CN119097618A (cg-RX-API-DMAC10.html)
AU (2) AU2020231189B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021017203A2 (cg-RX-API-DMAC10.html)
CA (1) CA3131948A1 (cg-RX-API-DMAC10.html)
DK (1) DK3934637T3 (cg-RX-API-DMAC10.html)
ES (1) ES2990183T3 (cg-RX-API-DMAC10.html)
FI (1) FI3934637T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20241150T1 (cg-RX-API-DMAC10.html)
HU (1) HUE068527T2 (cg-RX-API-DMAC10.html)
IL (2) IL321899A (cg-RX-API-DMAC10.html)
LT (1) LT3934637T (cg-RX-API-DMAC10.html)
MA (1) MA55199B1 (cg-RX-API-DMAC10.html)
MD (1) MD3934637T2 (cg-RX-API-DMAC10.html)
MX (2) MX2021010568A (cg-RX-API-DMAC10.html)
PL (1) PL3934637T3 (cg-RX-API-DMAC10.html)
PT (1) PT3934637T (cg-RX-API-DMAC10.html)
RS (1) RS65849B1 (cg-RX-API-DMAC10.html)
SG (1) SG11202109512SA (cg-RX-API-DMAC10.html)
SI (1) SI3934637T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202400334T1 (cg-RX-API-DMAC10.html)
WO (1) WO2020178721A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
CN120157593A (zh) 2018-12-06 2025-06-17 内在生物技术有限公司 乙酰基-亮氨酸的氘代类似物
MD3989962T2 (ro) 2019-06-28 2025-12-31 Intrabio Ltd Gb Terapie combinată cu acetil-leucină și miglustat pentru tratamentul unei boli de depozitare lizozomală
WO2021144720A1 (en) 2020-01-13 2021-07-22 Intrabio Ltd Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers
WO2022125304A1 (en) * 2020-12-10 2022-06-16 Texas Tech University System Bcaa-lowering compounds for prevention and/or treatment of alzheimer's disease and related disorders
WO2022264037A1 (en) * 2021-06-14 2022-12-22 Intrabio Ltd. Branched-chain amino acid derivatives to treat disease
WO2024243004A2 (en) * 2023-05-19 2024-11-28 The Children's Hospital Of Philadelphia Compositions and methods for treating traumatic brain injury
WO2025166100A1 (en) * 2024-02-02 2025-08-07 SynGAP Research Fund Compositions and methods for treating neurodevelopmental disorders
WO2025175092A1 (en) * 2024-02-14 2025-08-21 Intrabio Inc. Acetyl leucine for treating syngap1-related disorders
TW202604470A (zh) * 2024-06-20 2026-02-01 美商音特拉拜歐公司 乙醯白胺酸用於治療神經發育障礙

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060063827A1 (en) * 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
FR2905600B1 (fr) * 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
TN2010000251A1 (fr) * 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
CA2803166C (en) 2010-06-25 2023-03-07 Shire Human Genetic Therapies, Inc. Cns delivery of therapeutic agents
US20140080885A1 (en) * 2012-09-13 2014-03-20 University Of South Florida (A Florida Non-Profit Corporation) Methods of treating traumatic brain injury
PT3445351T (pt) * 2016-04-19 2024-11-14 Intrabio Ltd Acetil-leucina ou um sal farmaceuticamente aceitável seu derivado para melhoria da mobilidade
TN2016000259A1 (en) * 2016-06-27 2017-10-06 Rekik Raouf Salbutamol (albuterol) eye protective medicament.
PT3482754T (pt) 2016-08-11 2021-02-03 Intrabio Ltd Composições farmacêuticas e utilizações contra os distúrbios de armazenamento lisossómico
TN2019000033A1 (fr) * 2016-08-11 2020-07-15 Intrabio Ltd Agents thérapeutiques pour maladies neurodégénératives
US20190046486A1 (en) * 2017-08-14 2019-02-14 Axcella Health Inc. Compositions and methods for the treatment of neuronal injury

Also Published As

Publication number Publication date
CA3131948A1 (en) 2020-09-10
EP3934637A1 (en) 2022-01-12
RS65849B1 (sr) 2024-09-30
SMT202400334T1 (it) 2024-09-16
HRP20241150T1 (hr) 2024-11-22
AU2020231189A1 (en) 2021-09-30
MA55199A (fr) 2022-01-12
AU2025204995A1 (en) 2025-07-17
EP4464378A3 (en) 2025-04-09
EP3934637B1 (en) 2024-07-31
CN114040757B (zh) 2024-09-20
KR102941068B1 (ko) 2026-03-18
MA55199B1 (fr) 2024-08-30
MD3934637T2 (ro) 2024-12-31
JP2024170602A (ja) 2024-12-10
WO2020178721A1 (en) 2020-09-10
IL285870B1 (en) 2025-08-01
BR112021017203A2 (pt) 2021-12-14
CN119097618A (zh) 2024-12-10
CN114040757A (zh) 2022-02-11
PL3934637T3 (pl) 2024-10-14
JP7555346B2 (ja) 2024-09-24
IL321899A (en) 2025-09-01
FI3934637T3 (fi) 2024-09-02
US20220142959A1 (en) 2022-05-12
EP4464378A2 (en) 2024-11-20
IL285870A (en) 2021-10-31
MX2024015063A (es) 2025-01-09
LT3934637T (lt) 2024-08-26
JP2022522819A (ja) 2022-04-20
MX2021010568A (es) 2021-11-12
ES2990183T3 (es) 2024-11-29
AU2020231189B2 (en) 2025-07-24
KR20250171484A (ko) 2025-12-08
HUE068527T2 (hu) 2025-01-28
IL285870B2 (en) 2025-12-01
DK3934637T3 (da) 2024-09-02
SG11202109512SA (en) 2021-09-29
KR20210135272A (ko) 2021-11-12
SI3934637T1 (sl) 2024-10-30

Similar Documents

Publication Publication Date Title
IL285870A (en) Leucine, acetyl leucine, and related analogs for treating disease
IL285782A (en) Compounds, compositions, and methods for the treatment of disease
IL288958A (en) Exosomes for the treatment of diseases
IL279260A (en) KDM1A inhibitors for the treatment of diseases
IL286000A (en) Asketamine for the treatment of depression
IL288937A (en) Improved treatment using eyp001
SI3834594T1 (sl) Kolo s strgalom za sejalnik
GB202203999D0 (en) Tissue products having macrofolds
EP3927375A4 (en) COMPOSITIONS FOR THE TREATMENT OF DISEASES
PL3285755T3 (pl) Chlorowodorek kreatyny do leczenia choroby Huntingtona
GB201908453D0 (en) Compounds for treating respiratory disease
GB201913988D0 (en) Novel treatment
IL291640A (en) Compounds of 1,8-naphthyridin-2-one for the treatment of autoimmune disease
IL289440A (en) A process for deprotection of oligonucleotides
GB201914296D0 (en) Treatment
GB201912365D0 (en) Treatment
GB201912482D0 (en) Aiuthentication
IL287840A (en) treatment system
HUE065591T2 (hu) Gyógyszer fertõzõ betegségek kezelésére
GB201911728D0 (en) Bacterial composistions for the treatment of disease
IL267426A (en) Peptides for the treatment of Sjogren's syndrome
GB201902579D0 (en) Treatment
GB201906969D0 (en) Tissue splayer
GB201917691D0 (en) Compounds for treating respiratory disease
GB201908451D0 (en) Compounds for treating respiratory disease